M&A is ready to explode, and that’s good news for pharma layoffs

This summer has been chock full of biotechs and pharmas laying off staff and slashing drug development programs. If more deals are made, though, that could slow down.

In August, Vir Biotechnology, UniQure and Arbutus joined the ranks of those tightening their belts. But while cuts will likely still happen in the short term, some industry watchers believe layoffs will ebb by the end of the year as M&A activity increases with companies looking to replenish the pipelines they pruned.